Overexpression of α-enolase correlates with poor survival in canine mammary carcinoma
1 Department of Pathology, St. Martin De Porres Hospital, No. 565, Section 2, Daya Road, Chiayi, 60069, Taiwan
2 Department and Graduate Institute of Veterinary Medicine, School of Veterinary Medicine, National Taiwan University, No. 1, Section 4, Roosevelt Road, Taipei, 10617, Taiwan
3 Graduate Institute of Medicine, Kaohsiung Medical University, No. 100, Shih-Chuan 1st Road, Kaohsiung, 80708, Taiwan
4 National Institute of Cancer Research, National Health Research Institutes, No.367, Shengli Road, Tainan, 70456, Taiwan
5 Cancer Center, Kaohsiung Medical University Hospital, No. 100, Tzyou 1st Road, Kaohsiung, 80708, Taiwan
BMC Veterinary Research 2011, 7:62 doi:10.1186/1746-6148-7-62Published: 21 October 2011
α-Enolase (ENO1) is a key glycolytic enzyme implicated in the development of many human cancers including breast cancer. Increased expression of ENO1 has recently been reported in estrogen (ER)-positive human breast cancer patients. The present study examined the expression of ENO1 and assessed its significance in canine mammary carcinoma.
Immunohistochemical staining was employed to investigate the expression of ENO1 in 82 cases of canine mammary tumor (32 benign tumors and 50 carcinomas). Quantification of immunohistochemistry was carried out using Quick score and the results showed cytoplasmic ENO1 overexpression in 9 of the 50 carcinomas (18%). Overexpression of ENO1 correlated significantly with shorter cause-specific survival (P = 0.019), but was not associated with ER positivity in canine mammary carcinoma.
Our findings suggest that overexpression of ENO1 may be used as a prognostic marker for poor outcome in canine mammary carcinoma.